Pharmacy Medical News about Diabetes Mellitus, Type 2 Insulin

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Statins and cancer risk

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT
Current Medical Research and Opinion, 10/22/09

Strojek K et al. – With respect to HbA1c, BIAsp 30 fulfilled the statistical criteria for non–inferiority and superiority to insulin glargine and, according to pre–defined criteria, the improvements in HbA1c are considered clinically equivalent. Subjects had an increased risk of minor nocturnal hypoglycemia with BIAsp 30. There were no differences in treatment satisfaction between the two groups.

Exclusive Author Commentary
Krzysztof Strojek, 10/22/09

Hypoglycemic treatment of type 2 diabetic patients must be focused on normalization of blood glucose without adverse effects. The study showed that initiation of insulin should be individualized. Both algorithms brought the similar treatment satisfaction while BIAsp30 was associated with better glycemic control. On the other hand in the group of patients with higher risk of hypoglycemia, especially nocturnal, insulin initiation with glargine should be considered as alternative option.

<< Previous
Clinical pharmacy-led disease and medicine management programme...

Next >>
Renal protective effect of RAAS blockade across the renal...